The mode of action of CTLA-4 blockade in humans has not been elucidated completely, but it is likely to involve an expansion of the T-cell repertoire, most likely dependent on an intact process of tumor antigen cross-presentation in secondary and tertiary lymphoid structures. Here, CTLA4 is linked to neoplasm.